Oncternal Therapeutics, Inc.
DelistedCIK 1260990fmd_13Z4GZ5EKGK62GJPDYRAD8AE1EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2024, 59 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 3 | 2 | 3 | 4 | 1 | 1 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 21 | 14 | 17 | 21 | 0 | 0 | 0 | 0 | 0 | 30 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 30 | 22 | 26 | 31 | 10 | 36 | 21 | 36 | 46 | 42 |
| Operating income | (30) | (22) | (26) | (31) | (8) | (33) | (18) | (31) | (45) | (42) |
| Interest expense | – | – | – | – | 0 | – | – | – | – | – |
| Interest and investment income | – | – | – | – | 0 | 0 | 0 | 0 | 1 | 2 |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | 1 | (1) | 0 | 0 | – | – |
| Income before taxes | (39) | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | (39) | – | – | – | – | – | – | – | – | – |
| Net income | (39) | (19) | (18) | (30) | (7) | (34) | (17) | (31) | (44) | (39) |
| Net income to common shareholders | (39) | (22) | (18) | (30) | – | – | – | – | – | – |